Today: 19 March 2026
Subscribe
Browse Category

NYSE:JNJ 4 February 2026 - 10 March 2026

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson Moves Tecvayli Earlier in Europe After FDA Myeloma Nod

Johnson & Johnson filed with the European Medicines Agency to expand Tecvayli’s use as a solo treatment for adults with relapsed or refractory multiple myeloma after one prior therapy. The filing follows U.S. approval of Tecvayli with Darzalex last week and is supported by a phase 3 trial showing Tecvayli reduced disease progression or death by 71% versus standard care.
10 March 2026
···
Johnson & Johnson stock price slips as FDA fast-tracks nipocalimab; what investors watch next

Johnson & Johnson stock price slips as FDA fast-tracks nipocalimab; what investors watch next

Johnson & Johnson shares fell 0.7% to $245.07 Wednesday after its lupus drug nipocalimab received FDA Fast Track status. The stock lagged a broader market rally, with the S&P 500 ETF up nearly 1%. Investors weighed pipeline progress against ongoing legal risks and recent defensive trading. Johnson & Johnson will present at the Barclays Global Healthcare Conference on March 10.
4 March 2026
··
Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx stock surges toward $115 buyout price after Gilead deal sets new ceiling

Arcellx shares surged 78% to $113.92 after Gilead Sciences agreed to acquire the company for $115 per share in cash, plus a $5 contingent payout tied to anito-cel sales, valuing Arcellx at up to $7.8 billion. The companies expect to close the deal in Q2 2026. Trading volume in Arcellx topped 11 million shares by mid-morning. Gilead shares fell 0.5%.
23 February 2026
····
Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson stock price: JNJ heads into Monday as Tremfya data lands and dividend date nears

Johnson & Johnson shares closed at $242.49 on Friday, down 1.8%. The company released new three-year Tremfya data in ulcerative colitis over the weekend. J&J stock goes ex-dividend Feb. 24, with a $1.30-per-share payout set for March 10. A potential $20 billion sale of its DePuy Synthes orthopedics unit remains under discussion.
22 February 2026
···
Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson stock price: JNJ heads into Monday with DePuy sale talk and Tremfya data

Johnson & Johnson shares fell 1.8% to $242.49 Friday after Reuters reported the company is preparing a potential $20 billion sale of its DePuy Synthes orthopedics unit. J&J released new long-term data for Tremfya in ulcerative colitis, showing 80.8% remission at week 140. The company did not comment on the reported DePuy sale. Investors await management updates in March and April.
21 February 2026
··
Johnson & Johnson stock price slips after hours as healthcare lags — what’s next for JNJ

Johnson & Johnson stock price slips after hours as healthcare lags — what’s next for JNJ

Johnson & Johnson shares fell 0.6% to $238.64 in after-hours trading Monday as healthcare stocks lagged, despite gains in the broader market. The company will present at the Barclays Global Healthcare Conference on March 10. J&J faces over 67,500 talc lawsuits, with a New Jersey court last week disqualifying a plaintiffs’ firm. The board declared a $1.30 quarterly dividend, with the stock going ex-dividend Feb. 24.
10 February 2026
·
Johnson & Johnson stock price: JNJ near 52-week high as talc ruling, heart-device data set up Monday

Johnson & Johnson stock price: JNJ near 52-week high as talc ruling, heart-device data set up Monday

A New Jersey appeals court disqualified Beasley Allen from representing plaintiffs in consolidated state talc cases against Johnson & Johnson; the firm plans to appeal. J&J shares closed up 0.93% at $239.99, near a 52-week high, before slipping slightly after hours. The company also reported positive pilot data for its investigational AFib platform.
8 February 2026
··
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
7 February 2026
··
P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

P&G stock price climbs in late trade as investors rotate to defensives — and an insider sale hits the tape

Procter & Gamble shares rose 1.1% to $158.61 in after-hours trading, outperforming broader market declines. CEO Ma. Fatima D. Francisco sold 8,000 shares at $158 each on Feb. 4, according to a regulatory filing. U.S. jobless claims increased to 231,000, while job openings fell to 6.542 million. P&G’s Gillette Venus announced a partnership with U.S. Figure Skating ahead of the Milano Cortina Winter Games.
6 February 2026
···
JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

JNJ stock rises as Johnson & Johnson takes talc shareholder fight to U.S. Supreme Court

Johnson & Johnson shares rose 1.3% to $237.59 after the company asked the U.S. Supreme Court to review a shareholder lawsuit over talc safety claims. The petition challenges a Third Circuit ruling on class certification standards. The case is separate from ongoing talc injury suits. Investors are also watching for new data on J&J’s atrial fibrillation devices at a cardiology event this week.
5 February 2026
··
Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next

Johnson & Johnson stock holds near highs as FDA flags Impella heart-pump issue — what to watch next

The FDA issued an early alert on Abiomed Impella RP heart pumps, citing a pressure sensor defect linked to 22 serious injuries but no deaths. Johnson & Johnson shares rose 0.6% to $234.47, holding steady after hours. Traders await further FDA updates and MedTech data at the AF Symposium on Feb. 6. The S&P 500 fell 0.51% while the Dow gained 0.53%.
5 February 2026
··
Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson stock price rises as RBC hikes target; JNJ data catalysts line up next

Johnson & Johnson shares rose 1% to $235.50 Wednesday, bucking a broader market decline. RBC raised its price target to $255, citing strong financials despite ongoing talc litigation. New data showed ERLEADA cut prostate cancer death risk by 51% versus darolutamide. Investors await updates at the AF Symposium on Feb. 6 and a TD Cowen event on March 3.
4 February 2026
···
1 2 3 … 8

Stock Market Today

  • Goldman Sachs Stock Quote Price and Forecast
    March 19, 2026, 9:10 AM EDT. The Goldman Sachs Group, Inc. operates in financial services through three key segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment covers investment banking and equity and debt investments. Asset and Wealth Management focuses on direct-to-consumer banking including lending and deposits. Platform Solutions offers consumer credit and point-of-sale financing. Founded in 1869 and based in New York, Goldman Sachs is a major player in global finance. Investors often watch its stock closely due to its diverse revenue streams across banking, wealth management, and consumer finance.
Go toTop